search
Back to results

NSAID RCT for Prevention of Altitude Sickness

Primary Purpose

Spectrum of Altitude-associated Neurologic Forms of Altitude

Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ibuprofen 600mg orally three times daily
Sponsored by
Naval Health Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Spectrum of Altitude-associated Neurologic Forms of Altitude focused on measuring Spectrum of Altitude-associated acute mountain sickness, hypoxia, high altitude headache, high altitude cerebral edemat is.....

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

INCLUSION CRITERIA:

Active duty military

Current in their medical screening

EXCLUSION CRITERIA:

Upper respiratory tract infection or influenza

Have had a reaction to Ibuprofen, aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Stayed the night at an altitude of greater than 6,700 feet within the last 7 days

Headache at baseline

Have altitude sickness or more than one mild symptom of any severity on the Lake Louise Questionnaire including headache, poor appetite, nausea, vomiting, fatigue, weakness, dizziness, and/or poor sleep (insomnia)

Low blood oxygen or low oxygen saturation (<90%)

Pregnant or cannot exclude the possibility of being pregnant, or have missed menses by over 7 days.

Have taken any of the following in 48 hours preceding enrollment: acetazolamide/Diamox, steroids (dexamethasone/Decadron, prednisone), theophylline, or diuretics such as Lasix

Have taken any of the following within 12 hours preceding enrollment: Ibuprofen/Motrin, Naprosyn/Naproxen/Aleve, aspirin, or Acetaminophen/Tylenol.

Have taken any other medication that may be known to have potential for drug-drug interactions with ibuprofen, including (but not limited to): ACE-inhibitor antihypertiensives, thiazide diuretics, furosemide, lithium, methotrexate, and H-2 Agonists.

Have any medical conditions which may make participation hazardous (*by self-report which can be clarified before enrollment with the study physicians as necessary), including:

  • Heart disease - Congestive heart failure, heart attack in the last month or severe coronary artery disease, or significant heart valve problems or other congenital problems.
  • Lung disease - Restrictive lung disease, chronic obstructive pulmonary disease (COPD), severe obstructive sleep apnea, or pulmonary hypertension of any cause.
  • Neurological disorders - Hydrocephalus, history of brain tumor, history of severe brain trauma or coma, pseudotumor cerebri, or severe uncontrolled headaches/migraine disorder (as diagnosed by a doctor).
  • Gastrointestinal - Known stomach ulcer or history of gastrointestinal bleeding.
  • Blood disorders - Anemia, leukemia, or other coagulopathies of any kind.
  • Kidney disease - Kidney failure or other known kidney disease.

General - The Principal Investigator and co-investigator reserve the right to exclude a potential participant with conditions that in their judgment are not listed above, but which would reasonably represent concern for the participant's health and welfare, including (but not limited to) conditions that may directly antagonize mechanisms of acclimatization to altitude, organ failure, metastatic/malignant neoplasm, space-occupying brain lesions or diagnoses typically known to raise intracranial pressure, and disorders that are likely to antagonize adequate respiration, blood oxygenation, and/or circulation.

Sites / Locations

  • Marine Mountain Warfare Training Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ibuprofen

placebo

Arm Description

Ibuprofen 600mg taken three times daily for four days.

Avicel placebo capsules three times daily for four days

Outcomes

Primary Outcome Measures

Change in the incidence of AMS as measured on the Lake Louise AMS Questionnaire across the study.
The measure is assessed twice daily for four days

Secondary Outcome Measures

1. Change in High Altitude Headache measured by the Visual Analog Scale (VAS) across the study.
The measure is assessed twice daily for four days
2. Change in cognitive performance as measured by King-Devick across the study.
The measure is assessed twice daily for four days
3. Change in the presence of anxiety and somatic symptoms using the BSI-12 screening tool across the study
The measure is assessed twice daily for four days
4. Change in the oxygen concentration using Pulse Oximetry across the study.
The measure is assessed twice daily for four days
5. Change in hydration status as measured by urine specific gravity across the study.
The measure is assessed twice daily for four days
6. Change in HAH incidence and severity as measured on the Lake Louise AMS Questionnaire across the study.
The measure is assessed daily for four days
7. Change in cognitive performance as measured by the Quickstick across the study
The measure is assessed twice daily for four days
8. Change in the presence of anxiety and somatic symptoms using the GAD-2 screening tool across the study
The measure is assesed twice daily for four days
9. Incidence of severe AMS as measured by a score of 6 or greater on the Lake Louise AMS Questionnaire.
The measure is assessed twice daily for four days

Full Information

First Posted
April 13, 2012
Last Updated
May 23, 2012
Sponsor
Naval Health Research Center
Collaborators
University of California, San Diego
search

1. Study Identification

Unique Protocol Identification Number
NCT01606527
Brief Title
NSAID RCT for Prevention of Altitude Sickness
Official Title
Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Unknown status
Study Start Date
July 2012 (undefined)
Primary Completion Date
October 2012 (Anticipated)
Study Completion Date
October 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Naval Health Research Center
Collaborators
University of California, San Diego

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed study is a prospective, randomized, double-blind, placebo-controlled clinical trial evaluating ibuprofen and placebo for the prevention of neurological forms of altitude illness [including high altitude headache (HAH), acute mountain sickness (AMS), high altitude cerebral edema (HACE), and an emerging concept of High Altitude Anxiety]. The study will take place in the spring and summer of 2012 at the Marine Corps Mountain Warfare Training Center in the Eastern Sierras near Bridgeport, California. US Marines from near sea level will participate in battalion-level training exercises at between 8,500-11,500 Feet, where some altitude illness is expected. Concurrent measures used to determine objective markers of altitude illness, such that validated clinical scales, rapid cognitive screening tests, will inform us of symptoms of altitude illness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spectrum of Altitude-associated Neurologic Forms of Altitude
Keywords
Spectrum of Altitude-associated acute mountain sickness, hypoxia, high altitude headache, high altitude cerebral edemat is.....

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ibuprofen
Arm Type
Experimental
Arm Description
Ibuprofen 600mg taken three times daily for four days.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Avicel placebo capsules three times daily for four days
Intervention Type
Drug
Intervention Name(s)
Ibuprofen 600mg orally three times daily
Other Intervention Name(s)
Motrin
Intervention Description
Ibuprofen is taken 600mg orally three times daily
Primary Outcome Measure Information:
Title
Change in the incidence of AMS as measured on the Lake Louise AMS Questionnaire across the study.
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Secondary Outcome Measure Information:
Title
1. Change in High Altitude Headache measured by the Visual Analog Scale (VAS) across the study.
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Title
2. Change in cognitive performance as measured by King-Devick across the study.
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Title
3. Change in the presence of anxiety and somatic symptoms using the BSI-12 screening tool across the study
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Title
4. Change in the oxygen concentration using Pulse Oximetry across the study.
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Title
5. Change in hydration status as measured by urine specific gravity across the study.
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Title
6. Change in HAH incidence and severity as measured on the Lake Louise AMS Questionnaire across the study.
Description
The measure is assessed daily for four days
Time Frame
Twice daily
Title
7. Change in cognitive performance as measured by the Quickstick across the study
Description
The measure is assessed twice daily for four days
Time Frame
Twice daily
Title
8. Change in the presence of anxiety and somatic symptoms using the GAD-2 screening tool across the study
Description
The measure is assesed twice daily for four days
Time Frame
Twice daily
Title
9. Incidence of severe AMS as measured by a score of 6 or greater on the Lake Louise AMS Questionnaire.
Description
The measure is assessed twice daily for four days
Time Frame
Twice Daily

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA: Active duty military Current in their medical screening EXCLUSION CRITERIA: Upper respiratory tract infection or influenza Have had a reaction to Ibuprofen, aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs). Stayed the night at an altitude of greater than 6,700 feet within the last 7 days Headache at baseline Have altitude sickness or more than one mild symptom of any severity on the Lake Louise Questionnaire including headache, poor appetite, nausea, vomiting, fatigue, weakness, dizziness, and/or poor sleep (insomnia) Low blood oxygen or low oxygen saturation (<90%) Pregnant or cannot exclude the possibility of being pregnant, or have missed menses by over 7 days. Have taken any of the following in 48 hours preceding enrollment: acetazolamide/Diamox, steroids (dexamethasone/Decadron, prednisone), theophylline, or diuretics such as Lasix Have taken any of the following within 12 hours preceding enrollment: Ibuprofen/Motrin, Naprosyn/Naproxen/Aleve, aspirin, or Acetaminophen/Tylenol. Have taken any other medication that may be known to have potential for drug-drug interactions with ibuprofen, including (but not limited to): ACE-inhibitor antihypertiensives, thiazide diuretics, furosemide, lithium, methotrexate, and H-2 Agonists. Have any medical conditions which may make participation hazardous (*by self-report which can be clarified before enrollment with the study physicians as necessary), including: Heart disease - Congestive heart failure, heart attack in the last month or severe coronary artery disease, or significant heart valve problems or other congenital problems. Lung disease - Restrictive lung disease, chronic obstructive pulmonary disease (COPD), severe obstructive sleep apnea, or pulmonary hypertension of any cause. Neurological disorders - Hydrocephalus, history of brain tumor, history of severe brain trauma or coma, pseudotumor cerebri, or severe uncontrolled headaches/migraine disorder (as diagnosed by a doctor). Gastrointestinal - Known stomach ulcer or history of gastrointestinal bleeding. Blood disorders - Anemia, leukemia, or other coagulopathies of any kind. Kidney disease - Kidney failure or other known kidney disease. General - The Principal Investigator and co-investigator reserve the right to exclude a potential participant with conditions that in their judgment are not listed above, but which would reasonably represent concern for the participant's health and welfare, including (but not limited to) conditions that may directly antagonize mechanisms of acclimatization to altitude, organ failure, metastatic/malignant neoplasm, space-occupying brain lesions or diagnoses typically known to raise intracranial pressure, and disorders that are likely to antagonize adequate respiration, blood oxygenation, and/or circulation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jeffrey H Gertsch, MD
Phone
619-543-6891
Email
jgertsch@ucsd.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey H Gertsch, MD
Organizational Affiliation
Naval Health Research Center - San Diego
Official's Role
Principal Investigator
Facility Information:
Facility Name
Marine Mountain Warfare Training Center
City
Bridgeport
State/Province
California
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darren Thomas, MD
Email
darren.thomas@usmc.mil
First Name & Middle Initial & Last Name & Degree
Darren Thomas, MD

12. IPD Sharing Statement

Learn more about this trial

NSAID RCT for Prevention of Altitude Sickness

We'll reach out to this number within 24 hrs